Development of p300-targeting degraders with enhanced selectivity and onset of degradation

Authors:

Abstract
P300 and CBP are paralogous epigenetic regulators and promising therapeutic targets for which TPD offers the potential to achieve paralog-selective degradation.
Funding Information
  • Children's Cancer Research Fund
  • Paula and Rodger Riney Foundation
  • Congressionally Directed Medical Research Programs (HT9425-23-1-0456)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR055685)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR081228)